Seeking Alpha
 

Vericel Corporation (VCEL)

- NASDAQ
  • Wed, Aug. 12, 9:42 AM
    • Vericel (VCEL +1.5%) Q2 results: Revenues: $13.6M (+209.1%); COGS: $6.9M (+38.0%); R&D Expense: $3.4M (-22.7%); SG&A: $5.6M (+55.6%); Operating Loss: ($2.3M) (+72.9%); Net Loss: ($2.2M) (+52.2%); Loss Per Share: ($0.16) (+83.0%); Quick Assets: $129.9M (+10.1%).
    • No guidance given.
    | Comment!
  • Wed, Aug. 12, 7:35 AM
    • Vericel (NASDAQ:VCEL): Q2 EPS of -$0.16 beats by $0.05.
    • Revenue of $13.6M (+207.0% Y/Y) beats by $2.29M.
    • Press Release
    | Comment!
  • Fri, May 15, 9:00 AM
    • Vericel (VCEL +1.9%)  Q1 results : Revenues: $10.8M; COGS: $5.6M; R&D Expense: $4.4M (+33.3%); SG&A: $5.5M (+292.9%); Operating Loss: ($4.6M) (+1.7%); Net Loss: ($4.9M) (+18.3%); Loss Per Share: ($0.27) (+78.6%); Quick Assets: $25.9M (-14.5%).
    • No guidance given.
    | Comment!
  • Thu, May 14, 4:13 PM
    • Vericel (NASDAQ:VCEL): Q1 EPS of -$0.27 misses by $0.06.
    • Revenue of $10.8M misses by $0.33M.
    • Press Release
    | Comment!
  • Tue, Mar. 24, 6:20 AM
    • Vericel (VCEL -2.1%) Q4 results: Revenues: $14.7M (+999%); COGS: $6.8M (+999%); R&D Expense: $5.8M (+75.8%); SG&A: $4.5M (+181.3%); Operating Loss: ($2.3M) (+53.1%); Net Loss: ($2.4M) (+17.2%); Loss Per Share: ($0.17) (+82.5%).
    • FY2014 results: Revenues: $28.8M (+999%); COGS: $17.3M (+999%); R&D Expense: $21.3M (+41.1%); SG&A: $13.8M (+133.9%); Operating Loss: ($23.5M) (-11.9%); Net Loss: ($19.9M) (-27.6%); Loss Per Share: ($2.23) (+67.9%); Quick Assets: $30.3M (+274.1%).
    • No guidance given.
    | Comment!
  • Mon, Mar. 23, 4:04 PM
    • Vericel (NASDAQ:VCEL): Q4 EPS of -$0.17 may not be comparable to consensus of -$0.47.
    • Revenue of $14.7M beats by $4M.
    • Press Release
    | Comment!
  • Nov. 13, 2014, 9:47 AM
    • Aastrom Biosciences (ASTM +3.4%) Q3 results: Revenues: $9.7M; COGS: $5.5M; R&D Expense: $7.8M (+200.0%); SG&A: $4.3M (+290.9%); Operating Loss: ($8M) (-122.2%); Net Loss: ($6.9M) (-200.0%); Loss Per Share: ($0.82) (+31.7%); Quick Assets: $37.6M (+364.2%).
    • No guidance given.
    | Comment!
  • Nov. 13, 2014, 8:21 AM
    • Aastrom Biosciences (NASDAQ:ASTM): Q3 EPS of -$0.52 beats by $0.14.
    • Revenue of $9.66M beats by $2.93M.
    • Press Release
    | Comment!
  • Nov. 5, 2014, 5:13 PM
    • Aastrom Biosciences (NASDAQ:ASTM) will report Q3 results on November 13 before the open. The conference call will begin at 8:30 am ET.
    • Consensus view is a loss of ($0.66) per share on revenues of $6.7M.
    | Comment!
  • Aug. 14, 2014, 8:30 AM
    • Aastrom Biosciences (NASDAQ:ASTM) Q2 results: Revenues: $4.4M (+999%); Operating Expenses: $7.9M (+51.7%); Net Loss: ($4.6M) (+5.1%); Loss Per Share: ($0.94) (+65.4%); Quick Assets: $7.3M (-9.9%).
    • No financial guidance given.
    | Comment!
  • Aug. 14, 2014, 7:34 AM
    • Aastrom Biosciences (NASDAQ:ASTM): Q2 EPS of -$0.94 may not be comparable to consensus of -$1.02.
    • Press Release
    | Comment!
  • May 15, 2014, 6:01 PM
    | Comment!
  • Mar. 13, 2014, 4:51 PM
    | Comment!
  • Nov. 12, 2013, 5:21 PM
    • Aastrom Biosciences (ASTM): FQ3 EPS of -$0.06 beats by $1.96. (PR)
    | 5 Comments
  • Aug. 7, 2013, 6:04 PM
    • Aastrom (ASTM): Q2 EPS of -$0.11 beats by $0.03. (PR)
    | Comment!
  • May 9, 2013, 11:15 AM
    Aastrom Biosciences (ASTM -4.1%) slips today despite posting a Q1 net loss of -$0.15, which was narrower than the prior year and beat analysts estimates for a loss of $0.19 per share. The company also reported cash guidance, saying that it had a total of $9.2M in cash and cash equivalents, compared to $13.6 million in cash and cash equivalents in December. The cash used for operations during Q1 came to $6.8M.
    | Comment!
Visit Seeking Alpha's
VCEL vs. ETF Alternatives
Company Description
Vericel Corpis engaged in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two cell therapy products including Carticel and Epicel.
Sector: Healthcare
Industry: Biotechnology
Country: United States